Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Equities research analysts at Leerink Swann upped their FY2017 earnings per share (EPS) estimates for Alexion Pharmaceuticals in a note issued to investors on Thursday. Leerink Swann analyst now anticipates that the biopharmaceutical company will earn $5.05 per share for the year, up from their previous estimate of $5.02. Leerink Swann currently has a “Buy” rating and a $169.00 price objective on the stock. Leerink Swann also issued estimates for Alexion Pharmaceuticals’ Q4 2017 earnings at $1.34 EPS.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm had revenue of $859.00 million for the quarter, compared to analysts’ expectations of $864.34 million. During the same quarter in the previous year, the business posted $1.23 EPS. The company’s quarterly revenue was up 7.5% on a year-over-year basis.

Several other equities analysts have also issued reports on ALXN. Zacks Investment Research lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Royal Bank of Canada lifted their price target on Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Stifel Nicolaus lowered their price target on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a research report on Tuesday, October 24th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $130.00 price target (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research report on Thursday, January 4th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have issued a buy rating to the stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $153.10.

Shares of Alexion Pharmaceuticals (NASDAQ ALXN) opened at $121.05 on Friday. Alexion Pharmaceuticals has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a market cap of $27,040.00, a price-to-earnings ratio of 54.04, a PEG ratio of 1.02 and a beta of 1.17. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35.

Large investors have recently modified their holdings of the business. Jennison Associates LLC raised its position in Alexion Pharmaceuticals by 720.0% in the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after buying an additional 4,682,336 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Alexion Pharmaceuticals by 4,509.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock valued at $124,037,000 after purchasing an additional 864,967 shares during the last quarter. USA Financial Portformulas Corp purchased a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter valued at about $3,632,000. IFC Holdings Incorporated FL purchased a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter valued at about $861,000. Finally, Chicago Equity Partners LLC purchased a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter valued at about $320,000. 94.27% of the stock is owned by institutional investors and hedge funds.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 2,553 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the transaction, the chief executive officer now owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.35% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/01/20/leerink-swann-research-analysts-boost-earnings-estimates-for-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.